AU2003215826A1 - Pyranon and pyrandion inhibitors of hepatitis c virus rna-dependent rna polymerase - Google Patents

Pyranon and pyrandion inhibitors of hepatitis c virus rna-dependent rna polymerase

Info

Publication number
AU2003215826A1
AU2003215826A1 AU2003215826A AU2003215826A AU2003215826A1 AU 2003215826 A1 AU2003215826 A1 AU 2003215826A1 AU 2003215826 A AU2003215826 A AU 2003215826A AU 2003215826 A AU2003215826 A AU 2003215826A AU 2003215826 A1 AU2003215826 A1 AU 2003215826A1
Authority
AU
Australia
Prior art keywords
hepatitis
inhibitors
pyrandion
pyranon
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003215826A
Other languages
English (en)
Inventor
Allen J. Borchardt
Michael Paul Goble
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp SRL
Original Assignee
Pfizer Corp Belgium
Pfizer Corp SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp Belgium, Pfizer Corp SRL filed Critical Pfizer Corp Belgium
Publication of AU2003215826A1 publication Critical patent/AU2003215826A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/32Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
AU2003215826A 2002-04-01 2003-03-21 Pyranon and pyrandion inhibitors of hepatitis c virus rna-dependent rna polymerase Abandoned AU2003215826A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36938102P 2002-04-01 2002-04-01
US60/369,381 2002-04-01
PCT/IB2003/001206 WO2003082848A1 (en) 2002-04-01 2003-03-21 Pyranon and pyrandion inhibitors of hepatitis c virus rna-dependent rna polymerase

Publications (1)

Publication Number Publication Date
AU2003215826A1 true AU2003215826A1 (en) 2003-10-13

Family

ID=28675577

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003215826A Abandoned AU2003215826A1 (en) 2002-04-01 2003-03-21 Pyranon and pyrandion inhibitors of hepatitis c virus rna-dependent rna polymerase

Country Status (11)

Country Link
US (1) US6878727B2 (enExample)
EP (1) EP1490350B1 (enExample)
JP (1) JP2005526102A (enExample)
AT (1) ATE337309T1 (enExample)
AU (1) AU2003215826A1 (enExample)
BR (1) BR0308856A (enExample)
CA (1) CA2480583C (enExample)
DE (1) DE60307804T2 (enExample)
ES (1) ES2268394T3 (enExample)
MX (1) MXPA04009672A (enExample)
WO (1) WO2003082848A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DOP2003000641A (es) * 2002-05-10 2003-11-15 Pfizer Inhibidores de las arn polimerasa dependiente de arn del virus de las hepatitis c y composiciones y tratamiento que los usan
US7148226B2 (en) * 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
IN2012DN04853A (enExample) 2004-02-20 2015-09-25 Boehringer Ingelheim Int
US7115749B2 (en) 2004-10-29 2006-10-03 Schering Corporation Substituted 5-oxo pyrazoles and [1,2,4]triazoles as antiviral agents
EP1881828A4 (en) * 2005-05-20 2009-06-03 Valeant Res & Dev TREATMENT OF HEPATITIS C (HCV) USING SUB-THERAPEUTIC DOSES OF RIBAVIRIN
US7816348B2 (en) * 2006-02-03 2010-10-19 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
WO2008047694A1 (fr) * 2006-10-13 2008-04-24 Aska Pharmaceutical Co., Ltd. Procédé de fabrication d'un composé benzothiazole
EP2494991A1 (en) 2007-05-04 2012-09-05 Vertex Pharmaceuticals Incorporated Combination therapy for the treatment of HCV infection
CA2693495A1 (en) * 2007-08-03 2009-02-12 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
EP2188274A4 (en) * 2007-08-03 2011-05-25 Boehringer Ingelheim Int VIRAL POLYMERASE HEMMER
EA201000948A1 (ru) 2007-12-19 2011-02-28 Бёрингер Ингельхайм Интернациональ Гмбх Ингибиторы вирусной полимеразы

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1140049A (en) * 1977-12-22 1983-01-25 Dke J.E. Helgstran Pharmaceutical preparations from derivatives of hydroxycarbonylphosphonic acid
US6174868B1 (en) * 1992-09-10 2001-01-16 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of hepatitis C virus-associated diseases
US5846964A (en) * 1993-07-19 1998-12-08 Tokyo Tanabe Company Limited Hepatitis C virus proliferation inhibitor
IL129871A (en) * 1994-05-06 2003-11-23 Pharmacia & Upjohn Inc Process for preparing 4-phenyl-substituted octanoyl-oxazolidin-2-one intermediates that are useful for preparing pyran-2-ones useful for treating retroviral infections
AU777040B2 (en) * 1999-02-22 2004-09-30 Shire Biochem Inc. (1,8) naphthyridine derivatives having antiviral activity
AR034127A1 (es) * 2000-07-21 2004-02-04 Schering Corp Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento

Also Published As

Publication number Publication date
CA2480583A1 (en) 2003-10-09
EP1490350A1 (en) 2004-12-29
BR0308856A (pt) 2005-02-22
WO2003082848A1 (en) 2003-10-09
ES2268394T3 (es) 2007-03-16
MXPA04009672A (es) 2004-11-12
DE60307804D1 (de) 2006-10-05
ATE337309T1 (de) 2006-09-15
US6878727B2 (en) 2005-04-12
CA2480583C (en) 2008-07-15
JP2005526102A (ja) 2005-09-02
EP1490350B1 (en) 2006-08-23
DE60307804T2 (de) 2007-01-18
US20030195239A1 (en) 2003-10-16

Similar Documents

Publication Publication Date Title
DE60319820D1 (de) Pyrazoloä1,5-aüpyrimidin-verbindungen als antivirale agentien
UY27798A1 (es) Inhibidores de la arn polimerasa dependiente de arn del virus de la hepatits c y composiciones y tratamientos que los usan.
EA200501689A1 (ru) Соединения в качестве ингибиторов вируса гепатита c
IL180933A0 (en) Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same
YU56903A (sh) Nukleozidni derivati kao inhibitori rnk-zavisne rnk virusne polimeraze
WO2004000858A3 (en) Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
WO2004003138A3 (en) Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
NO20070194L (no) Fremgangsmater for behandling av hepatitt C
NO20045247L (no) Nukleosidderivater for behandling av hepatitt C-virusinfeksjon
NL1025544A1 (nl) Remmers van rna-afhankelijk rna-polymerase van hepatitis-c-virus en preparaten en behandelingen waarbij ze worden gebruikt.
NO20062428L (no) Kombinasjoner for HCV-behandling
AU2003215826A1 (en) Pyranon and pyrandion inhibitors of hepatitis c virus rna-dependent rna polymerase
EP1663105A4 (en) CYCLOALKYL HETEROCYCLES FOR TREATING HEPATITIS C VIRUS
WO2006043153A3 (en) Use of zinc and copper chelators for the treatment of viral diseases
WO2004052905A3 (en) Antiviral nucleoside derivatives
AU2003287216A1 (en) Gb virus c and methods of treating viral infections
WO2004006848A3 (en) Combination therapies with ftc for the treatment of hepatitis b virus infection
TW200614989A (en) Inhibitors of HCV replication
AU2003299493A8 (en) Compositions and methods for the treatment of hepatitis c virus infection
HK1065534A (en) Proline compounds as ns3-serine protease inhibitors for use in treatment of hepatitis c virus infection
HK1068796A (en) Nucleosides preparation thereof and use as inhibitors of rna viral polymerases

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase